• Je něco špatně v tomto záznamu ?

Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial

PA. Brogan, B. Arch, H. Hickey, J. Anton, E. Iglesias, E. Baildam, K. Mahmood, G. Cleary, E. Moraitis, C. Papadopoulou, MW. Beresford, P. Riley, S. Demir, S. Ozen, G. Culeddu, DA. Hughes, P. Dolezalova, LV. Hampson, J. Whitehead, D. Jayne, N....

. 2021 ; 73 (9) : 1673-1682. [pub] 20210731

Jazyk angličtina Země Spojené státy americké

Typ dokumentu hodnocení ekvivalence, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024988

Grantová podpora
SR/20094 Versus Arthritis - United Kingdom

OBJECTIVE: Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was undertaken to explore the relative effectiveness of CYC and MMF treatment in a randomized controlled trial (RCT). METHODS: This was an international, open-label, Bayesian RCT to investigate the relative effectiveness of CYC and MMF for remission induction in childhood PAN. Eleven patients with newly diagnosed childhood PAN were randomized (1:1) to receive MMF or intravenous CYC; all patients received the same glucocorticoid regimen. The primary end point was remission within 6 months while compliant with glucocorticoid taper. Bayesian distributions for remission rates were established a priori for MMF and CYC by experienced clinicians and updated to posterior distributions on trial completion. RESULTS: Baseline disease activity and features were similar between the 2 treatment groups. The primary end point was met in 4 of 6 patients (67%) in the MMF group and 4 of 5 patients (80%) in the CYC group. Time to remission was shorter in the MMF group compared to the CYC group (median 7.1 weeks versus 17.6 weeks). No relapses occurred in either group within 18 months. Two serious infections were found to be likely linked to MMF treatment. Physical and psychosocial quality-of-life scores were superior in the MMF group compared to the CYC group at 6 months and 18 months. Combining the prior expert opinion with results from the present study provided posterior estimates of remission of 71% for MMF (90% credibility interval [90% CrI] 51, 83) and 75% for CYC (90% CrI 57, 86). CONCLUSION: The present results, taken together with prior opinion, indicate that rates of remission induction in childhood PAN are similar with MMF treatment and CYC treatment, and MMF treatment might be associated with better health-related quality of life than CYC treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024988
003      
CZ-PrNML
005      
20211026134228.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/art.41730 $2 doi
035    __
$a (PubMed)33760371
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Brogan, Paul A $u University College London Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
245    10
$a Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial / $c PA. Brogan, B. Arch, H. Hickey, J. Anton, E. Iglesias, E. Baildam, K. Mahmood, G. Cleary, E. Moraitis, C. Papadopoulou, MW. Beresford, P. Riley, S. Demir, S. Ozen, G. Culeddu, DA. Hughes, P. Dolezalova, LV. Hampson, J. Whitehead, D. Jayne, N. Ruperto, C. Tudur-Smith, D. Eleftheriou
520    9_
$a OBJECTIVE: Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was undertaken to explore the relative effectiveness of CYC and MMF treatment in a randomized controlled trial (RCT). METHODS: This was an international, open-label, Bayesian RCT to investigate the relative effectiveness of CYC and MMF for remission induction in childhood PAN. Eleven patients with newly diagnosed childhood PAN were randomized (1:1) to receive MMF or intravenous CYC; all patients received the same glucocorticoid regimen. The primary end point was remission within 6 months while compliant with glucocorticoid taper. Bayesian distributions for remission rates were established a priori for MMF and CYC by experienced clinicians and updated to posterior distributions on trial completion. RESULTS: Baseline disease activity and features were similar between the 2 treatment groups. The primary end point was met in 4 of 6 patients (67%) in the MMF group and 4 of 5 patients (80%) in the CYC group. Time to remission was shorter in the MMF group compared to the CYC group (median 7.1 weeks versus 17.6 weeks). No relapses occurred in either group within 18 months. Two serious infections were found to be likely linked to MMF treatment. Physical and psychosocial quality-of-life scores were superior in the MMF group compared to the CYC group at 6 months and 18 months. Combining the prior expert opinion with results from the present study provided posterior estimates of remission of 71% for MMF (90% credibility interval [90% CrI] 51, 83) and 75% for CYC (90% CrI 57, 86). CONCLUSION: The present results, taken together with prior opinion, indicate that rates of remission induction in childhood PAN are similar with MMF treatment and CYC treatment, and MMF treatment might be associated with better health-related quality of life than CYC treatment.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a kyselina mykofenolová $x terapeutické užití $7 D009173
650    _2
$a polyarteritis nodosa $x farmakoterapie $7 D010488
650    _2
$a indukce remise $x metody $7 D012074
650    _2
$a výsledek terapie $7 D016896
655    _2
$a hodnocení ekvivalence $7 D000073843
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Arch, Barbara $u University of Liverpool, Liverpool, UK
700    1_
$a Hickey, Helen $u University of Liverpool, Liverpool, UK
700    1_
$a Anton, Jordi $u St. Joan de Déu Hospital, Barcelona, Spain
700    1_
$a Iglesias, Este $u St. Joan de Déu Hospital, Barcelona, Spain
700    1_
$a Baildam, Eileen $u Alder Hey Children's NHS Foundation Trust, Liverpool, UK
700    1_
$a Mahmood, Kamran $u Alder Hey Children's NHS Foundation Trust, Liverpool, UK
700    1_
$a Cleary, Gavin $u Alder Hey Children's NHS Foundation Trust, Liverpool, UK
700    1_
$a Moraitis, Elena $u Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
700    1_
$a Papadopoulou, Charalampia $u Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
700    1_
$a Beresford, Michael W $u University of Liverpool, Liverpool, UK
700    1_
$a Riley, Phil $u Royal Manchester Children's Hospital, Manchester, UK
700    1_
$a Demir, Selcan $u Hacettepe University, Ankara, Turkey
700    1_
$a Ozen, Seza $u Hacettepe University, Ankara, Turkey
700    1_
$a Culeddu, Giovanna $u Bangor University, Bangor, UK
700    1_
$a Hughes, Dyfrig A $u Bangor University, Bangor, UK
700    1_
$a Dolezalova, Pavla $u General University Hospital in Prague and Charles University, Prague, Czech Republic
700    1_
$a Hampson, Lisa V $u Lancaster University, Lancaster, UK
700    1_
$a Whitehead, John $u Lancaster University, Lancaster, UK
700    1_
$a Jayne, David $u University of Cambridge, Cambridge, UK
700    1_
$a Ruperto, Nicola $u Instituto Giannina Gaslini, IRCCS, UOSID Centro Trial, Genoa, Italy
700    1_
$a Tudur-Smith, Catrin $u University of Liverpool, Liverpool, UK
700    1_
$a Eleftheriou, Despina $u University College London Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
773    0_
$w MED00188151 $t Arthritis & rheumatology (Hoboken, N.J.) $x 2326-5205 $g Roč. 73, č. 9 (2021), s. 1673-1682
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33760371 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134234 $b ABA008
999    __
$a ok $b bmc $g 1714157 $s 1145495
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 73 $c 9 $d 1673-1682 $e 20210731 $i 2326-5205 $m Arthritis & rheumatology $n Arthritis Rheumatol $x MED00188151
GRA    __
$a SR/20094 $p Versus Arthritis $2 United Kingdom
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace